ELITE PHARMACEUTICALS INC /NV/ (ELTP)

Every figure below is the company's own, as filed. Nothing is estimated and nothing is smoothed — a period the filing does not support is left blank rather than drawn. Quarters are the company's own, counted from its financial year ending 03-31. Amounts in USD.

2Y 5Y 10Y All
Quarterly Annual TTM

Revenue Quarterly

0 15M 30M 45M Q2 '22: 8.6M Q3 '22: 9M Q4 '22: 7.7M Q1 '23: 7.7M Q2 '23: 8.6M Q3 '23: 9.3M Q4 '23: 8.6M Q1 '24: 9M Q2 '24: 14.2M Q3 '24: 15.5M Q4 '24: 17.9M Q1 '25: 18.8M Q2 '25: 18.9M Q3 '25: 14.4M Q4 '25: 32M Q1 '26: 40.2M Q2 '26: 36.3M Q3 '26: 31.6M Q4 '26: 40.7M Q1 '27: 32.4M Q3 '22 Q2 '23 Q1 '24 Q4 '24 Q3 '25 Q2 '26 Q1 '27

Gross Profit Quarterly

0 10M 20M 30M Q2 '22: 3.8M Q3 '22: 4M Q4 '22: 3.4M Q1 '23: 4M Q2 '23: 3.8M Q3 '23: 4.9M Q4 '23: 3.4M Q1 '24: 4.8M Q2 '24: 6.4M Q3 '24: 7M Q4 '24: 8.1M Q1 '25: 8.5M Q2 '25: 8.2M Q3 '25: 6.1M Q4 '25: 17.3M Q1 '26: 27.2M Q2 '26: 14.1M Q3 '26: 13M Q4 '26: 20.8M Q1 '27: 13.5M Q3 '22 Q2 '23 Q1 '24 Q4 '24 Q3 '25 Q2 '26 Q1 '27

Operating Income Quarterly

0 8M 16M 24M Q1 '22: 965.2K Q2 '22: 1.4M Q3 '22: 1.8M Q4 '22: 851.7K Q1 '23: 1M Q2 '23: 1.1M Q3 '23: 2M Q1 '24: 1.6M Q2 '24: 1.9M Q3 '24: 3.5M Q4 '24: 3.7M Q1 '25: 3.9M Q2 '25: 3.5M Q3 '25: 1.1M Q4 '25: 11.2M Q1 '26: 21.7M Q2 '26: 8.2M Q3 '26: 9M Q4 '26: 10.2M Q1 '27: 7.5M Q2 '22 Q1 '23 Q1 '24 Q4 '24 Q3 '25 Q2 '26 Q1 '27

Net Income Quarterly

-14M -7M 0 7M 14M 21M Q1 '22: 2.4M Q2 '22: 1.8M Q3 '22: 2.3M Q4 '22: 2.4M Q1 '23: 305.9K Q2 '23: 1.5M Q3 '23: 3M Q1 '24: 1.1M Q2 '24: 14.9M Q3 '24: 706.4K Q4 '24: 3.3M Q1 '25: 615.8K Q2 '25: -11M Q3 '25: -10.9M Q4 '25: 17M Q1 '26: -5.9M Q2 '26: 13.7M Q3 '26: 18.6M Q4 '26: 18.5M Q1 '27: 5.9M Q2 '22 Q1 '23 Q1 '24 Q4 '24 Q3 '25 Q2 '26 Q1 '27

Cost of Revenue Quarterly

0 8M 16M 24M Q2 '22: 4.8M Q3 '22: 5M Q4 '22: 4.3M Q1 '23: 3.7M Q2 '23: 4.8M Q3 '23: 4.3M Q4 '23: 5.2M Q1 '24: 4.2M Q2 '24: 7.7M Q3 '24: 8.5M Q4 '24: 9.8M Q1 '25: 10.3M Q2 '25: 10.7M Q3 '25: 8.2M Q4 '25: 14.7M Q1 '26: 13M Q2 '26: 22.2M Q3 '26: 18.6M Q4 '26: 20M Q1 '27: 18.8M Q3 '22 Q2 '23 Q1 '24 Q4 '24 Q3 '25 Q2 '26 Q1 '27

Operating Cash Flow Quarterly

-6M 0 6M 12M 18M Q2 '22: 153.8K Q3 '22: 3M Q4 '22: 1.6M Q1 '23: -557.5K Q2 '23: 1.5M Q3 '23: -567.9K Q4 '23: 3M Q1 '24: -2.7M Q2 '24: -235.9K Q3 '24: -2.4M Q4 '24: 2.1M Q1 '25: 3.1M Q2 '25: 1.5M Q3 '25: -1.1M Q4 '25: 3.9M Q1 '26: 14.8M Q2 '26: 5.1M Q3 '26: -5.3M Q4 '26: 9.1M Q1 '27: 10.1M Q3 '22 Q2 '23 Q1 '24 Q4 '24 Q3 '25 Q2 '26 Q1 '27

Free Cash Flow Quarterly

-10M -5M 0 5M 10M 15M Q2 '21: 1.8M Q3 '21: 1.2M Q1 '22: 1.7M Q2 '22: 6.4K Q3 '22: 3M Q4 '22: 1.3M Q1 '23: -652.1K Q2 '23: -3.6M Q3 '23: -568.6K Q4 '23: 2.4M Q4 '24: 1.7M Q1 '25: 2.4M Q2 '25: 1.4M Q3 '25: -1.1M Q4 '25: 3.2M Q1 '26: 14.6M Q2 '26: 5M Q3 '26: -5.5M Q4 '26: 8.7M Q1 '27: 9.3M Q3 '21 Q3 '22 Q2 '23 Q4 '24 Q3 '25 Q2 '26 Q1 '27

Operating cash flow minus capital expenditure.

Shares Outstanding Quarterly

0 400M 800M 1.2B Q3 '20: 829.4M Q1 '21: 1B Q2 '21: 913.6M Q3 '21: 1B Q1 '22: 1B Q2 '22: 1B Q3 '22: 1B Q1 '23: 1B Q2 '23: 1B Q3 '23: 1B Q1 '24: 1B Q2 '24: 1B Q3 '24: 1B Q1 '25: 1.1B Q2 '25: 1.1B Q3 '25: 1.1B Q1 '26: 1.1B Q2 '26: 1.1B Q3 '26: 1.1B Q1 '27: 1.1B Q1 '21 Q1 '22 Q1 '23 Q1 '24 Q1 '25 Q1 '26 Q1 '27

Weighted average diluted, as the filer reports it for each period. An average cannot be added across periods, so this one is always shown per period the filer tagged rather than as a trailing year.

EPS TTM

-0.03 -0.01 0.00 0.01 0.03 0.04 Q2 '22: 0.00 Q3 '22: 0.00 Q4 '22: 0.01 Q1 '23: 0.01 Q2 '23: 0.01 Q3 '23: 0.01 Q4 '23: 0.00 Q1 '24: 0.00 Q2 '24: 0.01 Q3 '24: 0.01 Q4 '24: 0.01 Q1 '25: 0.01 Q2 '25: -0.01 Q3 '25: -0.02 Q4 '25: 0.00 Q1 '26: -0.01 Q2 '26: 0.01 Q3 '26: 0.03 Q4 '26: 0.02 Q1 '27: 0.04 Q3 '22 Q2 '23 Q1 '24 Q4 '24 Q3 '25 Q2 '26 Q1 '27

The filer's own published earnings a share for each quarter, four quarters added up. The company page divides trailing net income by the share count instead, which lands within about 1% of this and is not the same sum, so the two are named differently rather than presented as one figure.